PT-141 Nasal Spray (10mg)
Specyfikacja techniczna
| Czystość (HPLC) | ≥99% (HPLC) |
| Numer CAS | 189691-06-3 |
| Forma | White lyophilized powder |
| Przechowywanie | -20°C |
| Sekwencja | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Masa cząsteczkowa | 1,025.21 g/mol |
| Forma soli | Acetate |
| Rozpuszczalność | Soluble in water |
PT-141 Nasal Spray (10mg)
Cena katalogowa w EUR · HU, SK, CZ, PL
- Eurozone (EUR)270,00 EUR
- Węgry (HU)270,00 EUR≈ 108 000 Ft
- Słowacja (SK)270,00 EUR
- Czechy (CZ)270,00 EUR≈ 6 750 Kč
- Polska (PL)270,00 EUR≈ 1147,50 zł
Ta sama cena katalogowa w EUR przy dostawie na Węgry, Słowację, Czechy i Polskę. Płatność w EUR.
Orientacyjne kwoty HUF, CZK i PLN przeliczone z EUR; Słowacja stosuje EUR. Kursy przybliżone. Płatność w EUR.
PT-141 — aerozol do nosa 10 mg — forma donosowa PT-141 dla badań szybkiego wchłaniania przeznosowego. Wyłącznie RUO — do badań laboratoryjnych; nie do spożycia przez ludzi.
Wyłącznie do badań laboratoryjnych.
Nie do spożycia przez ludzi, zastosowań weterynaryjnych ani diagnostycznych.
From the Peptide Explorer
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Key Mechanisms
- ›MC4R agonism (central, hypothalamic)
- ›MC3R partial agonism
- ›CNS-mediated arousal pathway
- ›Dopaminergic downstream signaling
- ›Independent of vascular mechanisms
Primary Research Areas
- ›Hypoactive sexual desire
- ›Melanocortin receptor pharmacology
- ›Central arousal pathways
- ›Female sexual dysfunction
Key Research Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Overview
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Origin: Derived from Melanotan II; developed by Palatin Technologies
Mechanism of Action
- MC4R agonism (central, hypothalamic)
- MC3R partial agonism
- CNS-mediated arousal pathway
- Dopaminergic downstream signaling
- Independent of vascular mechanisms
Primary Research Areas
- Hypoactive sexual desire
- Melanocortin receptor pharmacology
- Central arousal pathways
- Female sexual dysfunction
Key Published Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
PT-141 Nasal Spray (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Specyfikacja badawcza
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobacz standardy jakości →
Przechowywanie i obsługa
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water